Bioequivalence study comparing Zubsolv with Suboxone sublingual tablets

Trial Profile

Bioequivalence study comparing Zubsolv with Suboxone sublingual tablets

Completed
Phase of Trial: Phase I

Latest Information Update: 18 Oct 2016

At a glance

  • Drugs Buprenorphine/naloxone (Primary)
  • Indications Opioid abuse
  • Focus Pharmacokinetics; Registrational
  • Most Recent Events

    • 18 Oct 2016 New trial record
    • 04 Oct 2016 Results published in an Orexo media release.
    • 04 Oct 2016 According to an Orexo media release, a Marketing Authorization Application (MAA) has been submitted for Zubsolv sublingual tablet to the EMA for the treatment of opioid dependence based on data from this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top